Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

9.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K
T Cell Types and Functions01:24

T Cell Types and Functions

963
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
963
Antimicrobial Proteins01:23

Antimicrobial Proteins

951
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
951

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anakinra for recurrent pericarditis: a retrospective evaluation of long-term effectiveness, initiation timing and tapering.

Rheumatology international·2026
Same author

Disease-related and psychosocial factors associated with difficult-to-manage and treatment-refractory axial spondyloarthritis: insights from the Greek AxSpA Registry.

Rheumatology international·2026
Same author

Targeting inflammatory persistence in axial spondyloarthritis: from cytokine blockade to pathway convergence.

Expert opinion on therapeutic targets·2026
Same author

Cutaneous Manifestations in Psoriatic Arthritis: Phenotypes, Clinical Burden, and Therapeutic Implications.

Rheumatology and therapy·2026
Same author

The effect of Nintedanib on KL-6 levels in patients with interstitial lung disease: A systematic review and meta-analysis.

Autoimmunity reviews·2026
Same author

Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment.

Annals of the rheumatic diseases·2026

Related Experiment Video

Updated: Jun 15, 2025

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.0K

Interferon Inhibition in SLE: From Bench to Bedside.

Dimitrios Deligeorgakis1, Elpida Skouvaklidou1, Christina Adamichou1

  • 1Department of Rheumatology, 4th Department of Internal Medicine, Hippokration Hospital, Thessaloniki, Greece.

Mediterranean Journal of Rheumatology
|August 28, 2024
PubMed
Summary

Systemic lupus erythematosus (SLE) management is challenging. Novel therapies targeting type I interferons (IFNs), like anifrolumab, show promise in treating this chronic autoimmune disease by blocking harmful IFN activity.

Keywords:
anifrolumabefficacysafetysystemic lupus erythematosustype I interferon

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.4K
Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection
09:11

Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection

Published on: July 16, 2019

9.1K

Related Experiment Videos

Last Updated: Jun 15, 2025

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.0K
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.4K
Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection
09:11

Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection

Published on: July 16, 2019

9.1K

Area of Science:

  • Immunology
  • Rheumatology
  • Molecular Biology

Background:

  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant morbidity and mortality.
  • Current treatments involve immunosuppressants and corticosteroids, with frequent disease flares.
  • Recent research highlights the critical role of type I interferons (IFNs) in SLE pathogenesis.

Purpose of the Study:

  • To review the latest research on the role and mechanisms of type I IFNs in SLE.
  • To summarize the development and advances in novel therapeutic drugs targeting the IFN pathway for SLE.

Main Methods:

  • Review of recent scientific literature on type I IFNs and SLE.
  • Analysis of clinical trial data for IFN-targeting therapies.
  • Examination of the mechanism of action for anifrolumab.

Main Results:

  • Type I IFNs are key players in the pathogenesis of SLE.
  • Anifrolumab, a monoclonal antibody targeting the type I IFN receptor, has been approved for active SLE.
  • Inhibition of the type I IFN pathway represents a promising therapeutic strategy.

Conclusions:

  • Targeting type I IFNs offers a novel approach to managing SLE.
  • Anifrolumab demonstrates the clinical efficacy of IFN pathway inhibition.
  • Further research into IFN-mediated mechanisms can lead to improved SLE treatments.